References
- Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19:1893–1907.10.1158/1055-9965.EPI-10-0437
- Ikeda N, Hayashi A, Iwasaki K, et al. Comprehensive diagnostic bronchoscopy of central type early stage lung cancer. Lung Cancer. 2007;56:295–302.10.1016/j.lungcan.2007.01.009
- Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis. 2014;130:561–565.
- Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727–729.10.1126/science.285.5428.727
- Chen Y, Lin G, Guo ZQ, et al. Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PLoS ONE. 2013;8:e69044.10.1371/journal.pone.0069044
- Tamaki S, Sanefuzi N, Kawakami M, et al. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Hum Immunol. 2008;69:88–93.10.1016/j.humimm.2008.01.010
- Rebmann V, Schütt P, Brandhorst D, et al. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol. 2007;123:114–120.10.1016/j.clim.2006.11.007
- Goldstraw P. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (Seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2:706–714.10.1097/JTO.0b013e31812f3c1a
- Molina R, Holdenrieder S, Auge JM, et al. Diagnostic relevance of circulating biomarkers in patients with lung cancer. Cancer Biomark. 2016;6:163–178.
- Barak V, Holdenrieder S, Nisman B, et al. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomark. 2016;6:191–196.
- Chen J, Xu H, Zhu XX. Abnormal expression levels of sMICA and NKG2D are correlated with poor prognosis in pancreatic cancer. Ther Clin Risk Manag. 2015;12:11–18.
- Li JJ, Pan K, Gu MF, et al. Prognostic value of soluble MICA levels inthe serum of patients with advanced hepatocellularcarcinoma. Chin J Cancer. 2013;32:141–148.10.5732/cjc.012.10025
- Koguchi Y, Hoen HM, Bambina SA, et al. Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab. Cancer Res. 2015;75:5084–5092.10.1158/0008-5472.CAN-15-2303
- Rebmann V, Schütt P, Brandhorst D, et al. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol. 2007;123:114–120.10.1016/j.clim.2006.11.007
- Samuels S, Ferns DM, Meijer D, et al. High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. Tissue Antigens. 2015;85:476–483.10.1111/tan.12562